非小细胞肺癌(NSCLC)是一种发病率较高的恶性肿瘤。复发,以及人类的死亡率,对人类健康构成重大威胁。此外,NSCLC的有效早期诊断仍然主要受限于缺乏准确的生物标志物.因此,迫切需要了解NSCLC发病机制和治疗失败的潜在机制.甲基转移酶样3(METTL3)是其成员转移甲基的家族的典型成员。它与调节NSCLC的发病机制有关,以及赋予对非小细胞肺癌治疗的耐药性。已经报道了METTL3用于NSCLC治疗的靶向。然而,METTL3与NSCLC之间的关系还有待证实.在这次审查中,我们通过总结METTL3在NSCLC发病机制中的研究来讨论相关的相互关系,治疗抗性,和临床应用。目前的研究表明,METTL3表达的上调推动了肿瘤发生,programming,和NSCLC的治疗耐药。因此,我们认为METTL3是NSCLC诊断和预后的优良候选生物标志物.METTL3的治疗靶向在NSCLC治疗中具有显著的潜力。这篇综述概述了METTL3和NSCLC之间的关联。这将为基础和临床研究提供有价值的参考。
Non-small cell lung cancer (NSCLC) is a malignant cancer that with high incidence, recurrence, and mortality rates in human beings, posing significant threats to human health. Moreover, effective early diagnosis of NSCLC remains limited primarily by the lack of accurate biomarkers. Therefore, there is an urgent need to understand the mechanisms underlying NSCLC pathogenesis and treatment failure. Methyltransferase-like 3 (METTL3) is a prototypical member of a family of which its members transfer methyl groups. It has been implicated in modulating the pathogenesis of NSCLC, as well as conferring resistance to NSCLC therapeutics. The targeting of METTL3 for NSCLC treatment has been reported. However, the relationship between METTL3 and NSCLC remains to be demonstrated. In this review, we discuss relevant interrelationships by summarising the studies on METTL3 in NSCLC pathogenesis, therapeutic resistance, and clinical applications. Current research suggests that the upregulation of METTL3 expression propels the tumorigenesis, progression, and treatment resistance of NSCLC. Therefore, we propose that METTL3 is an excellent candidate biomarker for NSCLC diagnosis and prognosis. Therapeutic targeting of METTL3 has significant potential for NSCLC treatment. This review provides a summary of the association between METTL3 and NSCLC, which would be a valuable reference for both basic and clinical research.